NCT06687733View on ClinicalTrials.gov

Safety and Efficacy Study of NGGT002 in cPKU Adult Subjects

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

July 25, 2024

Primary Completion Date

July 30, 2026

Study Completion Date

July 30, 2031

Conditions
Phenylketonurias
Interventions
GENETIC

NGGT002

adeno-associated viral vector with human phenylalanine hydroxylase gene

Trial Locations (2)

Unknown

RECRUITING

First Affiliated Hospital of Bengbu Medical College, Bengbu

RECRUITING

Xinhua Hospital Affifiated to Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
lead

NGGT (Suzhou) Biotechnology Co., Ltd.

INDUSTRY